Omadacycline

Drug Profile

Omadacycline

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; PTK796

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Community-acquired pneumonia; Skin and soft tissue infections; Urinary tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Skin and soft tissue infections
  • Phase I Nosocomial infections; Urinary tract infections
  • Preclinical Acute sinusitis
  • Research Anthrax; Plague

Most Recent Events

  • 02 Nov 2016 Pharmacokinetics data from a phase Ib trial in Urinary tract infection released by Paratek Pharmaceuticals
  • 02 Nov 2016 Paratek Pharmaceuticals completes a phase Ib trial in Urinary tract infection in USA
  • 11 Oct 2016 Paratek establishes CRADA with U.S. Army Medical Research Institute of Infectious Diseases for the development of Omadacycline in Anthrax and plague
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top